Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829874) titled 'Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Biliary Tract Cancer (BTC)
Intervention:
Drug: QL1706 (Iparomlimab/Tuvonralimab)
Drug: Lenvatinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 20, 2026
Target Sample Size: 180
Countries of Recruitment:
China
To know more,...